[{"id":"4e8d1c5a-aa92-47e5-9dde-7cd5c8707088","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756556","created_at":"2023-03-06T15:01:55.600Z","updated_at":"2024-07-02T16:35:21.279Z","phase":"Phase 2","brief_title":"T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma","source_id_and_acronym":"NCT05756556","lead_sponsor":"ImmVira Pharma Co. Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • T3011"],"overall_status":"Suspended","enrollment":" Enrollment 68","initiation":"Initiation: 06/30/2024","start_date":" 06/30/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-01"},{"id":"8790b5b4-a08c-451b-a3e9-b8bd7f87117b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04527549","created_at":"2021-01-18T21:40:53.974Z","updated_at":"2024-07-02T16:35:45.270Z","phase":"Phase 2","brief_title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","source_id_and_acronym":"NCT04527549","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-06-22"},{"id":"2e9c47f2-4cd8-4fc4-bb34-ab7a99f8abdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263453","created_at":"2022-03-02T16:52:42.865Z","updated_at":"2024-07-02T16:35:46.842Z","phase":"Phase 2","brief_title":"HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation","source_id_and_acronym":"NCT05263453","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-05-31"},{"id":"589fc224-1f44-451f-847a-4d0ffa6361d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257424","created_at":"2021-01-18T10:36:10.936Z","updated_at":"2024-07-02T16:36:18.245Z","phase":"Phase 1/2","brief_title":"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma","source_id_and_acronym":"NCT02257424","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-01-20"},{"id":"02f5ddb1-babb-4841-9903-825b89a46917","acronym":"","url":"https://clinicaltrials.gov/study/NCT02199730","created_at":"2021-01-29T07:06:47.760Z","updated_at":"2024-07-02T16:37:15.333Z","phase":"Phase 2","brief_title":"S1320: Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma","source_id_and_acronym":"NCT02199730","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD4","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2017-12-22"},{"id":"56bf1530-3867-4ac6-bd63-b4d18ea65359","acronym":"","url":"https://clinicaltrials.gov/study/NCT02281734","created_at":"2021-10-27T09:53:25.922Z","updated_at":"2024-07-02T16:37:16.996Z","phase":"Phase 2","brief_title":"Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease and BRAF Mutation","source_id_and_acronym":"NCT02281734","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-19"}]